Answers are grounded in this paper and cite their sources.
A series of spiro-indolin-2-one derivatives were designed and synthesized as p53-MDM2 binding inhibitors. Though p53-MDM2 binding inhibitory and activities against p53 wild-type cell lines of most compounds were not that promising, some obtained structures showed moderate to strong inhibitory activities (IC50<0.08 μM) against p53 mutant cell lines (SW620), suggesting that these compounds may have different modes of action to p53 pathway, further studies on treatment of p53 mutant tumors are under investigation.cc
No takes yet. Share an insight, caveat, or question.
Liang et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: